BriaCell Therapeutics AI Stock Analysis
BriaCell Therapeutics (BCTX) AI Stock Analysis
BriaCell Therapeutics
(NASDAQ:BCTX)
No summary available
BriaCell Therapeutics (BCTX) vs. SPDR S&P 500 ETF (SPY)
- Market Cap
- $38.42M
- Dividend Yield
- ―
- Average Volume (3M)
- 250.76K
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 1.31
- Revenue Growth
- ―
- EPS Growth
- 87.83%
- Country
- US
- Employees
- 31
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
BriaCell Therapeutics Business Overview & Revenue Model
Company Description
BriaCell Therapeutics Corp. is a biotechnology company focused on immuno-oncology, dedicated to developing innovative immune-based therapies for cancer treatment. Its primary therapeutic candidate, Bria-IMT, is a whole-cell cancer vaccine currently u...
BriaCell Therapeutics Risk Analysis
BriaCell Therapeutics disclosed 50 risk factors in its most recent earnings report. BriaCell Therapeutics reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
0 New RisksBriaCell Therapeutics Peers Comparison
Overall Rating
TSE:MBX52Neutral
TSE:DOSE39Underperform
TSE:RVX39Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 52Neutral | CAD 40.41M | -7.79 | -18.83% | ― | -27.13% | -1752.63% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 39Underperform | CAD 12.40M | -4.04 | 42.51% | ― | -19.31% | 34.45% | |
| 39Underperform | CAD 25.82M | -1.62 | 11.24% | ― | ― | -28.45% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| BCTX | BriaCell Therapeutics | 3.06 | -5.44 | -64.00% | |
| TSE:DOSE | Rapid Dose Therapeutics Corp | 0.10 | -0.08 | -44.12% | |
| TSE:MBX | Microbix Biosystms | 0.28 | 0.04 | 14.58% | |
| TSE:RVX | Resverlogix Corp. | 0.07 | -0.04 | -31.82% | |
| TSE:GSD | Devonian Health Group, Inc. | 6.75 | -8.25 | -55.00% | |
| TSE:TTI | Thiogenesis Therapeutics Corp | 0.60 | -0.05 | -7.69% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
